FK506 vs. cyclosporin: Pathologic findings in 1067 endomyocardial biopsies

Cardiovascular Pathology

Volumn 12, Issue 2, 2003, Pages 73-76

  Gajjar, Nupoor A ^a,c   Kobashigawa, Jon A ^b   Laks, Hillel ^b   Espejo Vassilakis, Maria ^b   Fishbein, Michael C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclosporin; FK506; Quilty lesion; Rejection

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENDOCARDIUM; FEMALE; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART MUSCLE INJURY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0344089207     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(02)00164-3     Document Type: Article

References (19)

1. Billingham M.E. The post-surgical heart: the pathology of cardiac transplantation. Am J Cardiovasc Pathol. 1:1988;319-334.
2. Winters G.L. The challenge of endomyocardial biopsy interpretation in assessing cardiac allograft rejection. Curr Opin Cardiol. 12:1997;146-152.
3. Gopal S., Narasimhan U., Day J.D., Gao R., Kasper E.K., Chen C.L., Cina S., Robertson A.L., Hruban R.H. The Quilty lesion enigma: focal apoptosis/necrosis and lymphocyte subsets in human cardiac allografts. Pathol Int. 48:1998;191-198.
4. Nakhleh R.E., Copenhaver C.M., Werdin K., McDonald K., Kubo S.H., Strickler J.G. Lack of evidence for involvement of Epstein-Barr virus in the development of the "Quilty" lesion of transplanted hearts: an in situ hybridization study. J Heart Lung Transplant. 10:1991;504-507.
5. Joshi A. The Quilty effect: current knowledge and clinical implications. Transplant Proc. 30:1998;907-908.
6. Costanzo-Nordin M.R., Winters G.L., Fisher S.G., O'Sullivan J., Heroux A.L., Kao W., Mullen G.M., Johnson M.R. Endocardial infiltrates in the transplanted heart: clinical significance emerging from the analysis of 5026 endomyocardial biopsy specimens. J Heart Lung Transplant. 12:1993;741-747.
7. Zoja C., Furci L., Ghilardi F., Zilio P., Benigni A., Remuzzi G. Cyclosporin-induced endothelial injury. Lab Invest. 55:1986;455-462.
8. Freimark D., Czer L.S.C., Aleksic I., Ruan X.M., Admon D., Blanche C., Trento A., Fishbein M.C. Pathogenesis of Quilty lesion in cardiac allografts: relationship to reduced endocardial cyclosporine A. J Heart Lung Transplant. 14:1995;1197-1203.
9. Wiederrecht G., Lam E., Hung S., Martin M., Sigal N. The mechanism of action of FK-506 and cyclosporine A. Ann NY Acad Sci. 696:1993;9-19.
10. Ho S., Clipstone N., Timmermann L., Northrop J., Graef I., Fiorentino D., Nourse J., Crabtree G.R. The mechanism of action of cyclosporine A and FK506. Clin Immunol Immunopathol. 80:1996;S40-S45.
11. Ruhlmann A., Nordheim A. Effects of the immunosuppressive drugs CsA and FK506 on intracellular signaling and gene regulation. Immunobiology. 198(1-3):1997;192-206.
12. Gummert J.F. Newer immunosuppressive drugs: a review. J Am Soc Nephrol. 6:1999;1366-1380.
13. Taylor D.O., Barr M.L., Radovancevic B., Renlund D.G., Mentzer R.M., Smart F.W., Tolman D.E., Frazier O.H., Young J.B., VanVeldhuisen P. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 18:1999;336-345.
14. Kobashigawa J.A. Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine. Transplant Proc. 30:1998;1095-1097.
15. Billingham M.E., Cary N.R.B., Hammond E.H., Kemnitz J., Marboc C., McCallister H.A., Snovar D.C., Winters G.L., Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant. 9:1990;587-593.
16. Fishbein M.C., Bell G., Lones M.A., Czer L.S., Miller J.M., Harasty D., Trento A. Grade 2 cellular heart rejection: does it exist? J Heart Lung Transplant. 13:1994;1051-1057.
17. Meiser B.M., Uberfuhr P., Fuchs A., Schmidt D., Pfeiffer M., Paulus D., Schulze C., Wildhirt S., Scheidt W.V., Angermann C., Klauss V., Martin S., Reichenspurner H., Kreuzer E., Reichart B. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant. 8:1998;782-788.
18. Freudenberger R., Alexis J., Gass A., Fuster V., Badimon J. Antithrombotic effect of FK506 vs. cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy. J Heart Lung Transplant. 18:1999;1228-1231.
19. Klauss V., König A., Spes C., Meiser B., Rieber J., Siebert U., Regar E., Pfeiffer M., Reichart B., Theisen K., Mudra H. Cyclosporine versus tacrolimus (FK506) for prevention of cardiac allograft vasculopathy. Am J Cardiol. 85:2000;266-269.